Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
Last trade$6.40
Day change-$0.015 (-0.23%)
Day range$6.40 – $6.42
Volume109,129
Market cap$243M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$243.36M
Price / earnings
—
Price / book
-10.92×
Price / sales
2.14×
EV / sales
1.98×
EV / EBITDA
-60.13×
Profitability
Earnings per share
-$1.98
Return on assets
-32.85%
Return on equity
336.68%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0.25×
Current ratio
3.84×
Quick ratio
2.59×
Cash ratio
1.05×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
—
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LFCR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q1 FY2027 Jun 30, 2026
Q4 FY2026 Mar 31, 2026
Q2 FY2026 Sep 30, 2025
Q3 FY2025 Sep 30, 2025
Q1 FY2025 May 25, 2025
Q4 FY2025 Feb 23, 2025
Q2 FY2025 Aug 25, 2024
Revenue
$25.32M
$34.17M
$23.19M
$31.11M
$31.11M
$36.44M
$35.15M
$24.71M
Cost of revenue
$18.5M
$22.09M
$18.73M
$23.32M
$23.32M
$22.46M
$25.31M
$19.32M
Gross profit
$6.83M
$12.08M
$4.46M
$7.79M
$7.79M
$13.98M
$9.85M
$5.39M
Selling, general and administrative
$6.3M
$7.97M
$7.92M
$8.9M
$8.9M
$8.98M
$9.98M
$14.79M
Research and development
$1.42M
$1.54M
$1.22M
$1.96M
$1.96M
$2.1M
$2.05M
$2.19M
Total operating expenses
$7.72M
$9.51M
$9.13M
$10.86M
$10.86M
$8.56M
$12.02M
$16.97M
Operating income
-$894K
$2.57M
-$4.67M
-$3.07M
-$3.07M
$5.42M
-$2.18M
-$11.58M
Interest expense
-$8.1M
-$7.75M
-$7.35M
-$6.38M
-$6.38M
-$5.73M
-$5.59M
-$5.38M
Income before taxes
-$40.03M
-$6.13M
-$14.94M
-$9.66M
-$9.66M
-$1.11M
-$14.78M
-$16.26M
Income taxes
$51K
$23K
$43K
$333K
$333K
$33K
-$8K
-$25K
Net income
-$40.08M
-$6.16M
-$14.98M
-$9.99M
-$9.99M
-$1.15M
-$14.77M
-$16.23M
Net income attributable to common shareholders
-$41.03M
-$7.13M
-$15.93M
-$10.91M
-$10.91M
-$2.05M
-$15.65M
-$16.23M
EBITDA
-$894K
$2.57M
-$2.36M
-$1.09M
-$3.07M
$2.9M
-$102K
-$9.59M
Basic earnings per share
-$1.08
-$0.19
-$0.43
-$0.29
-$0.29
-$0.06
-$0.42
-$0.53
Diluted earnings per share
-$1.08
-$0.19
-$0.43
-$0.29
-$0.29
-$0.06
-$0.42
-$0.53
Recent news
Company coverage with links to the original publishers.
Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether MISTRAS Group's $20.35/share sale to H.I.G. Capital, Lifecore Biomedical's $6.28/share sale to Webster Equity Partners, and Marygold Companies' $2.00/share sale to Madison Dearborn Partners represent fair deals for shareholders. The firm may seek increased consideration, additional disclosures, and other relief on behalf of shareholders.
A proposed class action settlement of $3,750,000 has been reached on behalf of purchasers of Lifecore Biomedical, Inc. (NASDAQ: LFCR) securities between October 7, 2020, and March 19, 2024. The settlement requires court approval at a hearing scheduled for July 28, 2026. Class members must submit claim forms by July 7, 2026, to be eligible for distribution from the settlement fund.
Lifecore Biomedical announced it has signed a CDMO manufacturing services agreement with a new aesthetics customer for an established, market-approved product. This is the company's third commercial site transfer since October 2025. The product is expected to generate commercial revenue within 24 months and contribute to Lifecore's targeted 2029 revenue CAGR of 12%. The agreement demonstrates successful execution of the company's strategy to secure lower-risk, late-stage programs with faster paths to commercial revenue.
Johnson Fistel, PLLP announced investigations into potential securities law violations by Green Dot Corporation, Lifecore Biomedical, and Horizon Technology Finance on behalf of affected investors. Green Dot's stock declined approximately 7% following the company's announcement of delayed financial results for Q4 and full year 2025.
Johnson Fistel, PLLP announced investigations into three companies on March 16, 2026. Lifecore Biomedical issued disappointing 2026 revenue guidance of $120-125 million versus $141.4 million in 2025, citing customer loss and product launch delays, resulting in an 18% stock decline. The firm is also investigating Horizon Technology Finance and G-III Apparel Group for potential federal securities law violations.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.